Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schütte, M; Risch, T; Abdavi-Azar, N; Boehnke, K; Schumacher, D; Keil, M; Yildiriman, R; Jandrasits, C; Borodina, T; Amstislavskiy, V; Worth, CL; Schweiger, C; Liebs, S; Lange, M; Warnatz, HJ; Butcher, LM; Barrett, JE; Sultan, M; Wierling, C; Golob-Schwarzl, N; Lax, S; Uranitsch, S; Becker, M; Welte, Y; Regan, JL; Silvestrov, M; Kehler, I; Fusi, A; Kessler, T; Herwig, R; Landegren, U; Wienke, D; Nilsson, M; Velasco, JA; Garin-Chesa, P; Reinhard, C; Beck, S; Schäfer, R; Regenbrecht, CR; Henderson, D; Lange, B; Haybaeck, J; Keilholz, U; Hoffmann, J; Lehrach, H; Yaspo, ML.
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.
Nat Commun. 2017; 8(2):14262-14262
Doi: 10.1038/ncomms14262
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Golob-Schwarzl Nicole
- Haybäck Johannes
- Schweiger Caroline
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Colorectal carcinoma represents a heterogeneous entity, with only a fraction of the tumours responding to available therapies, requiring a better molecular understanding of the disease in precision oncology. To address this challenge, the OncoTrack consortium recruited 106 CRC patients (stages I-IV) and developed a pre-clinical platform generating a compendium of drug sensitivity data totalling >4,000 assays testing 16 clinical drugs on patient-derived in vivo and in vitro models. This large biobank of 106 tumours, 35 organoids and 59 xenografts, with extensive omics data comparing donor tumours and derived models provides a resource for advancing our understanding of CRC. Models recapitulate many of the genetic and transcriptomic features of the donors, but defined less complex molecular sub-groups because of the loss of human stroma. Linking molecular profiles with drug sensitivity patterns identifies novel biomarkers, including a signature outperforming RAS/RAF mutations in predicting sensitivity to the EGFR inhibitor cetuximab.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Aged, 80 and over -
- Animals -
- Antineoplastic Agents, Immunological - therapeutic use
- Biomarkers, Tumor - genetics
- Biomarkers, Tumor - metabolism
- Cetuximab - therapeutic use
- Colorectal Neoplasms - drug therapy
- Colorectal Neoplasms - genetics
- Colorectal Neoplasms - metabolism
- ErbB Receptors - antagonists & inhibitors
- ErbB Receptors - metabolism
- Gene Expression Profiling -
- Gene Expression Regulation, Neoplastic -
- Humans -
- Mice -
- Middle Aged -
- Xenograft Model Antitumor Assays -
- Young Adult -